<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666663</url>
  </required_header>
  <id_info>
    <org_study_id>18-25736_SPG_2018.09</org_study_id>
    <nct_id>NCT03666663</nct_id>
  </id_info>
  <brief_title>Sphenopalatine Ganglion Blocks RCT</brief_title>
  <acronym>SPGblock</acronym>
  <official_title>UCSF Sphenopalatine Ganglion Block Study- a Randomized Double Blind Placebo Controlled Trial to Compare Nasal Anesthetics for Migraine Prevention in Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RCT of Sphenopalatine Ganglion (SPG) Blocks using anesthetics vs. placebo for migraine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Migraine is a brain disorder with high prevalence. It is the 7th leading cause of&#xD;
      disability worldwide according the WHO.&#xD;
&#xD;
      SPG block is a treatment for migraine that has been used for two decades. It can be done by&#xD;
      needle injection of anesthetic to the region of the SPG. However, there are now multiple&#xD;
      catheter devices that can be used to non-invasively administer anesthetic topically through&#xD;
      the nasal cavity to the region of the SPG where the anesthetic is then absorbed through thin&#xD;
      membranes covering the SPG.&#xD;
&#xD;
      Various anesthetic agents have been studied however currently, to our knowledge, there is no&#xD;
      head to head comparison of the various anesthetics used. Studies of SPG blocks in the setting&#xD;
      of chronic migraine are few as compared to the use of SPG as acute treatment for migraine.&#xD;
&#xD;
      With the use of an RCT, we aim to determine the overall efficacy of SPG blocks used at longer&#xD;
      intervals than have been studied in the past as compared to placebo, as well as to examine&#xD;
      the relative efficacy of the anesthetics used most commonly and studied for SPG blocks.&#xD;
&#xD;
      We will be using an FDA cleared device, the Sphenocath which was developed and registered&#xD;
      with the FDA for this specific population and purpose. The study intervention is the standard&#xD;
      practice in the UCSF Headache Center to perform SPG blocks for our patients with chronic&#xD;
      migraine. The frequency we use in clinical practice and that we plan to study is less often&#xD;
      than in previous studies of this intervention in this population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">July 8, 2021</completion_date>
  <primary_completion_date type="Actual">July 8, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized placebo controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Reduction in Headache Days From Baseline to Month 8 of Treatment</measure>
    <time_frame>8 months</time_frame>
    <description>Reduction in headache days from baseline to month 8 of treatment as self- reported by the patients (yes/no) and as per headache diary and retrospective charts review documentation</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SPG blocks with lidocaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SPG blocks with bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SPG blocks with ropivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive SPG blocks with placebo (saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Nasal application using the Sphenocath device- cleared by FDA</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Nasal application using the Sphenocath device- cleared by FDA</description>
    <arm_group_label>Bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Nasal application using the Sphenocath device- cleared by FDA</description>
    <arm_group_label>Ropivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Saline using the Sphenocath device- cleared by FDA</description>
    <arm_group_label>Placebo (saline)</arm_group_label>
    <other_name>Placebo Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or more at time of consent&#xD;
&#xD;
          2. Current patients in the UCSF Headache Center eligible to receive SPG blocks for&#xD;
             migraine and would otherwise receive treatment clinically&#xD;
&#xD;
          3. Ability to provide consent for the research study&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Pregnant or breast feeding within 4 weeks of enrollment&#xD;
&#xD;
          2. Inability to communicate with the study team&#xD;
&#xD;
          3. Patients who cannot read and understand English&#xD;
&#xD;
          4. Deemed unsuitable for enrollment in study by the investigator&#xD;
&#xD;
          5. Allergy to local anesthetics or saline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Riggins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Headache Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Headache Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache. 1991 Jun;31(6):365-71.</citation>
    <PMID>1889975</PMID>
  </reference>
  <reference>
    <citation>Piagkou M, Demesticha T, Troupis T, Vlasis K, Skandalakis P, Makri A, Mazarakis A, Lappas D, Piagkos G, Johnson EO. The pterygopalatine ganglion and its role in various pain syndromes: from anatomy to clinical practice. Pain Pract. 2012 Jun;12(5):399-412. doi: 10.1111/j.1533-2500.2011.00507.x. Epub 2011 Sep 29. Review. Erratum in: Pain Pract. 2012 Nov;12(8):673.</citation>
    <PMID>21956040</PMID>
  </reference>
  <reference>
    <citation>Robbins MS, Robertson CE, Kaplan E, Ailani J, Charleston L 4th, Kuruvilla D, Blumenfeld A, Berliner R, Rosen NL, Duarte R, Vidwan J, Halker RB, Gill N, Ashkenazi A. The Sphenopalatine Ganglion: Anatomy, Pathophysiology, and Therapeutic Targeting in Headache. Headache. 2016 Feb;56(2):240-58. doi: 10.1111/head.12729. Epub 2015 Nov 30. Review.</citation>
    <PMID>26615983</PMID>
  </reference>
  <reference>
    <citation>Mehta D, Leary MC, Yacoub HA, El-Hunjul M, Kincaid H, Koss V, Wachter K, Malizia D, Glassman B, Castaldo JE. The Effect of Regional Anesthetic Sphenopalatine Ganglion Block on Self-Reported Pain in Patients With Status Migrainosus. Headache. 2019 Jan;59(1):69-76. doi: 10.1111/head.13390. Epub 2018 Jul 25.</citation>
    <PMID>30043973</PMID>
  </reference>
  <reference>
    <citation>Binfalah M, Alghawi E, Shosha E, Alhilly A, Bakhiet M. Sphenopalatine Ganglion Block for the Treatment of Acute Migraine Headache. Pain Res Treat. 2018 May 7;2018:2516953. doi: 10.1155/2018/2516953. eCollection 2018.</citation>
    <PMID>29862074</PMID>
  </reference>
  <reference>
    <citation>Mojica J, Mo B, Ng A. Sphenopalatine Ganglion Block in the Management of Chronic Headaches. Curr Pain Headache Rep. 2017 Jun;21(6):27. doi: 10.1007/s11916-017-0626-8. Review. Erratum in: Curr Pain Headache Rep. 2017 Nov 20;21(12 ):53. Mojica, Jeffery [corrected to Mojica, Jeffrey].</citation>
    <PMID>28432602</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2018</study_first_submitted>
  <study_first_submitted_qc>September 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <results_first_submitted>July 21, 2021</results_first_submitted>
  <results_first_submitted_qc>September 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 11, 2021</results_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03666663/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lidocaine</title>
          <description>Participants will receive SPG blocks with lidocaine.&#xD;
Lidocaine: Nasal application using the Sphenocath device- cleared by FDA</description>
        </group>
        <group group_id="P2">
          <title>Bupivacaine</title>
          <description>Participants will receive SPG blocks with bupivacaine&#xD;
Bupivacaine: Nasal application using the Sphenocath device- cleared by FDA</description>
        </group>
        <group group_id="P3">
          <title>Ropivacaine</title>
          <description>Participants will receive SPG blocks with ropivacaine&#xD;
Ropivacaine: Nasal application using the Sphenocath device- cleared by FDA</description>
        </group>
        <group group_id="P4">
          <title>Placebo (Saline)</title>
          <description>Participants will receive SPG blocks with placebo (saline)&#xD;
Placebo: Placebo Saline using the Sphenocath device- cleared by FDA</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lidocaine</title>
          <description>Participants will receive SPG blocks with lidocaine.&#xD;
Lidocaine: Nasal application using the Sphenocath device- cleared by FDA</description>
        </group>
        <group group_id="B2">
          <title>Bupivacaine</title>
          <description>Participants will receive SPG blocks with bupivacaine&#xD;
Bupivacaine: Nasal application using the Sphenocath device- cleared by FDA</description>
        </group>
        <group group_id="B3">
          <title>Ropivacaine</title>
          <description>Participants will receive SPG blocks with ropivacaine&#xD;
Ropivacaine: Nasal application using the Sphenocath device- cleared by FDA</description>
        </group>
        <group group_id="B4">
          <title>Placebo (Saline)</title>
          <description>Participants will receive SPG blocks with placebo (saline)&#xD;
Placebo: Placebo Saline using the Sphenocath device- cleared by FDA</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="1"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="3"/>
                    <count group_id="B5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="1"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="3"/>
                    <count group_id="B5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Reduction in Headache Days From Baseline to Month 8 of Treatment</title>
        <description>Reduction in headache days from baseline to month 8 of treatment as self- reported by the patients (yes/no) and as per headache diary and retrospective charts review documentation</description>
        <time_frame>8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>Participants will receive SPG blocks with lidocaine.&#xD;
Lidocaine: Nasal application using the Sphenocath device- cleared by FDA</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine</title>
            <description>Participants will receive SPG blocks with bupivacaine&#xD;
Bupivacaine: Nasal application using the Sphenocath device- cleared by FDA</description>
          </group>
          <group group_id="O3">
            <title>Ropivacaine</title>
            <description>Participants will receive SPG blocks with ropivacaine&#xD;
Ropivacaine: Nasal application using the Sphenocath device- cleared by FDA</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Saline)</title>
            <description>Participants will receive SPG blocks with placebo (saline)&#xD;
Placebo: Placebo Saline using the Sphenocath device- cleared by FDA</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Reduction in Headache Days From Baseline to Month 8 of Treatment</title>
          <description>Reduction in headache days from baseline to month 8 of treatment as self- reported by the patients (yes/no) and as per headache diary and retrospective charts review documentation</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>follow up appointments and chart review</desc>
      <group_list>
        <group group_id="E1">
          <title>Lidocaine</title>
          <description>Participants will receive SPG blocks with lidocaine.&#xD;
Lidocaine: Nasal application using the Sphenocath device- cleared by FDA</description>
        </group>
        <group group_id="E2">
          <title>Bupivacaine</title>
          <description>Participants will receive SPG blocks with bupivacaine&#xD;
Bupivacaine: Nasal application using the Sphenocath device- cleared by FDA</description>
        </group>
        <group group_id="E3">
          <title>Ropivacaine</title>
          <description>Participants will receive SPG blocks with ropivacaine&#xD;
Ropivacaine: Nasal application using the Sphenocath device- cleared by FDA</description>
        </group>
        <group group_id="E4">
          <title>Placebo (Saline)</title>
          <description>Participants will receive SPG blocks with placebo (saline)&#xD;
Placebo: Placebo Saline using the Sphenocath device- cleared by FDA</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Nina Riggins</name_or_title>
      <organization>UCSF</organization>
      <phone>7028064831</phone>
      <email>Nina.Riggins7@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

